Αρχική World News Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated, Locally... World News Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated, Locally Recurrent Inoperable or Metastatic TNBC Από Ogkologos - 28 Απριλίου, 2026 237 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Breast02 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June 5 Ιουνίου, 2025 Innovative cancer spinouts: 3 new projects get green light 13 Αυγούστου, 2021 Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... 6 Μαρτίου, 2024 FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC 2 Σεπτεμβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell... Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 New drug available for rare thyroid cancer on NHS in England
